Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers (Immune PDX)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03134027 |
Recruitment Status :
Suspended
(Suspended due to COVID-19.)
First Posted : April 28, 2017
Last Update Posted : December 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model. The hypothesis is that by using matched leukocytes and PDX from the same patient, rejection of the PDX by the host immune system will not be observed and therefore a preclinical model to study immunotherapy can be developed to study, understand and improve upon our current therapies. HSPCs will be collected from bone marrow aspirate obtained from a bone marrow biopsy.
The secondary objective is to use patient tumor biopsy samples or circulating tumor cell samples to develop additional preclinical models of GU cancers, particularly prostate cancer, that are clinically relevant by generating additional PDXs.
Condition or disease | Intervention/treatment |
---|---|
Genito Urinary Cancer Bladder Cancer Kidney Cancer Prostate Cancer | Procedure: Bone marrow biopsy Procedure: Tumor biopsy |
Study Type : | Observational |
Estimated Enrollment : | 30 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers |
Actual Study Start Date : | October 19, 2017 |
Estimated Primary Completion Date : | November 2021 |
Estimated Study Completion Date : | November 2021 |
Group/Cohort | Intervention/treatment |
---|---|
Subjects from which PDXs have been generated.
Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
|
Procedure: Bone marrow biopsy
Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection. |
Subjects without an existing PDX
Subjects with prostate cancer amenable to a tumor biopsy.
|
Procedure: Tumor biopsy
Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX. |
- Reconstitution of a matched human immune system in patient derived xenografts (PDXs) [ Time Frame: approximately 4 months ]Number of samples yielding a matched human immune system in immunodeficient mice resulting in a PDX with a humanized immune system.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria for Bone Marrow Biopsy:
- Patients with Genitourinary (GU) Cancers and presence of existing patient derived xenograft or planned collection of tumor for PDX generation
- Age ≥ 18 years.
- Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
- Ability to undergo bone marrow biopsy
- Laboratory requirements (Hematocrit 30%, Platelets 75,000 + 10^6/l and WBC 4000 X 10^6/l)
- Karnofsky performance status >70%
Exclusion Criteria for Bone Marrow Biopsy:
1. Participants with serious concurrent chronic or acute illness that would affect the safety of a bone marrow biopsy.
Inclusion Criteria for Tumor Biopsy
-
Patients with prostate cancer
a. Biopsies in this study for diseases other than prostate cancer are not permitted.
- Age ≥ 18 years.
- Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
-
Planned or willing to undergo a tumor biopsy. Biopsies may be for research or clinical purposes depending on the treating provider for men with prostate cancer. Biopsies in this study for diseases other than prostate cancer are not permitted
- For research only biopsies: At least one lymph node or bone metastatic amenable to a minimum risk biopsy in the opinion of the treating physician.
- For clinical purpose biopsies: There are no location or risk requirements.
- Laboratory requirements (Hematocrit 30%, Platelets 75,000 X 10^6/l and WBC 4000 X 10^6/l)
- Karnofsky performance status >70%
Exclusion Criteria for Tumor Biopsy:
1. Participants with serious concurrent chronic or acute illness that would affect the safety of a tumor biopsy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03134027
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Andrew Armstrong, MD, ScM | Duke Cancer Institute |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT03134027 |
Other Study ID Numbers: |
Pro00082398 |
First Posted: | April 28, 2017 Key Record Dates |
Last Update Posted: | December 21, 2020 |
Last Verified: | December 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Kidney Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms |
Urologic Neoplasms Urologic Diseases Kidney Diseases |